BCL2 and B-cell chronic lymphocytic leukemia: Because BCL2 protein levels progressively decline during CLL cycling (Figure 1D,F), we examined whether activated CLL clonal populations manifest progressively lesser vulnerability to venetoclax as they continue dividing.